Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The securities class action lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made materially false and misleading statements about the clinical prospects of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][4]. Company Overview - MoonLake Immunotherapeutics is facing a class action lawsuit due to claims regarding the efficacy of its drug candidate, sonelokimab (SLK), which is based on a unique Nanobody structure [3][4]. - The company’s stock price fell from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and showed inferior efficacy compared to a competitor [4]. Legal Context - The class period for the lawsuit is defined as March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [4][5]. - Hagens Berman, the law firm leading the litigation, is encouraging investors who suffered significant losses during this period to come forward and discuss their legal options [5][6]. Investor Actions - Investors who purchased MoonLake stock within the specified class period and experienced substantial losses are urged to contact Hagens Berman to explore potential legal recourse and the possibility of being appointed as Lead Plaintiff [5][6].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate, sonelokimab (SLK), leading to significant financial losses after disappointing trial results were announced [8]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that MoonLake misrepresented SLK as superior to competing monoclonal antibodies while failing to disclose that it targeted the same molecules as UCB's BIMZELX and had no proven superiority [8]. - Following the announcement of Phase 3 results on September 28, 2025, which showed SLK did not match BIMZELX's efficacy, MoonLake's stock price dropped nearly 90%, resulting in substantial losses for investors [8]. - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, are eligible to apply to be lead plaintiffs in the lawsuit by December 15, 2025 [8]. Group 2: Company Background - MoonLake Immunotherapeutics is a company listed on NASDAQ under the ticker MLTX, focusing on developing innovative therapies [8]. - The firm has faced scrutiny due to the performance of its sole drug candidate, which has been criticized for not delivering on its promised clinical advantages [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified class period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6] - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of misleading statements regarding its product SLK and its comparison to BIMZELX, which led to significant stock price decline following disappointing clinical trial results [2][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to contact them for discussing legal options [1]. - The firm is investigating claims against MoonLake and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the efficacy of SLK compared to BIMZELX [4]. Group 2: Financial Impact - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to BIMZELX, resulting in a stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [5]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 3: Company Background - MoonLake Immunotherapeutics is listed on NASDAQ under the ticker MLTX [2]. - The company is involved in the development of therapeutics, specifically focusing on Nanobodies and their clinical applications [4].

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][3][4]. Summary by Sections Lawsuit Details - The lawsuit claims that MoonLake's assertions regarding the superiority of its Nanobody technology were misleading, particularly in comparison to the FDA-approved competitor BIMZELX [3]. - The stock price plummeted from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and demonstrated inferior efficacy [4]. Timeline and Key Information - Class Period: March 10, 2024 – September 29, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Significant Stock Drop: 90% loss on September 29, 2025, due to failed trial results [4]. Next Steps for Investors - Investors who purchased MoonLake stock during the specified class period and incurred substantial losses are encouraged to contact Hagens Berman to explore legal options and potential appointment as Lead Plaintiff [5]. About Hagens Berman - Hagens Berman is a global plaintiffs' rights firm that focuses on corporate accountability and has secured over $2.9 billion for clients in similar cases [7].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 15, 2025 deadline for a securities class action [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting their own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, defendants made false or misleading statements regarding the efficacy of MoonLake's Nanobodies compared to traditional monoclonal antibodies, leading to investor losses when the truth was revealed [5].

Core Viewpoint - The complaint against MoonLake alleges violations of federal securities laws due to false and misleading statements regarding the efficacy and structure of its drug SLK compared to monoclonal antibodies like BIMZELX [2]. Group 1: Allegations and Legal Proceedings - The complaint claims that MoonLake and its executives failed to disclose that SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - It is alleged that SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [2]. - The complaint also states that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for positive statements about SLK's superiority [2]. Group 2: Market Reaction - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price dropped by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for the positive claims made about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no financial obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from March 10, 2024, to September 29, 2025 [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit a form online or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake made false and misleading statements regarding its product SLK, particularly in comparison to monoclonal antibodies like BIMZELX [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide a clinical advantage over traditional monoclonal antibodies [5].